NebuFlow

The company's patented technology utilizes Surface Acoustic Waves (SAWs) to aerosolise a wide range of drug formulations, including those that are difficult to deliver with conventional nebulisers like biologics, nanomedicines, and vaccines. This acoustic technology allows for precise control over the aerosol droplet size, ensuring that particles are small enough (under 5µm) for efficient deep lung deposition. This enhances the effectiveness of treatments for respiratory disorders such as asthma and COPD and unlocks systemic drug delivery via the lungs for cardiovascular and central nervous system disorders.

Nebu-Flow's business model centers on partnering with pharmaceutical companies to integrate its nebulisation engine into their drug delivery systems. Revenue is generated through technology licensing, collaborative development projects, grants, and equity investments. The company operates in the global inhalable drug and nebuliser markets, valued at approximately $33 billion and over $1 billion respectively in 2023. The company has secured significant funding, including a £1.7 million round in 2022 and a £4.7 million round in April 2024, from investors such as SCVC, Scottish Enterprise, Foresight WAE Technology, and SIS Ventures.

The management team includes experienced professionals from the pharmaceutical and medical device industries. Andrea Cusack joined as CEO in 2024, bringing over 25 years of experience from roles at GSK and Catalent. The chairman, Dr. John Pritchard, has over 25 years of experience in respiratory drug delivery with companies like GSK, AstraZeneca, and Philips.